# US 10,766,948 B2 · Monoclonal antibodies specific for the pIII antigen of human Adenovirus (ADV), produced and secreted by cell hybridomas, useful for detection and diagnosis of ADV infection > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,766,948 B2 - Document ID: US10766948B2 - Status: Granted - Kind: B2 - Application number: 16/070,730 - Filed: 2017-01-20 - Published: 2019-02-14 - Granted: 2020-09-08 - Earliest claimed: 2016-01-21 - Assignees: Pontificia Universidad Catolica De Chile - Applicants: Pontificia Universidad Catolica De Chile - Inventors: Susan Marcela Bueno Ramirez; Alexis Mikes Kalergis Parra; Jorge Eugenio Mora Alarcon - Web page: https://patentgrep.com/patent/US10766948B2 ## CPC - C07K 16/081: DNA viruses - A61P 31/12: Antivirals - G01N 33/54313: {the carrier being characterised by its particulate form} - G01N 33/56983: {Viruses} - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract The present invention refers to monoclonal antibodies, or fragments thereof, which recognize the pIII protein of the Adenovirus (ADV), useful for developing diagnostic methods of ADV infection in humans. Particularly, it refers to a monoclonal antibody or fragment thereof comprising a variable region of the heavy chain having a sequence with at least a 90%, 95% or 99% of identity with the SEQ ID No: 1 or SEQ ID No: 5 and a variable region of the light chain having a sequence with at least a 90%, 95% or 99% of identity with the SEQ ID No: 2 or SEQ ID No: 6. It also is addressed to the nucleotide sequences which define said antibodies, in vitro and/or ex vivo diagnostic methods of ADV infection in a biological sample using said monoclonal antibodies, and diagnostic kits for detecting ADV comprising at least one monoclonal antibody against ADV according to the above description. ## Claims ### Claim 1 A monoclonal antibody, or a fragment thereof, which binds to the pIII protein of Adenovirus (ADV), comprising a variable region of the heavy chain having a sequence with at least 90%, 95% or 99% identity with SEQ ID NO: 1 or SEQ ID NO: 5 and a variable region of the light chain having a sequence with at least 90%, 95% or 99% identity with SEQ ID NO: 2 or SEQ ID NO: 6. ### Claim 2 (depends on 1) The monoclonal antibody or fragment thereof, according to claim 1, wherein the antibody or fragment thereof is also bound to a label selected from the group consisting of fluorophores, biotin, radioisotopes, metals, proteins and enzymes. ### Claim 3 (depends on 1) A set of nucleotide sequences codifying a monoclonal antibody or a fragment thereof according to claim 1, comprising a sequence with at least 80%, 85%, 90%, 95% or 99% identity with SEQ ID NO: 3 or SEQ ID NO: 7, and their reverse complements, which codifies the variable region of the heavy chain of the antibody, and comprising a sequence with at least 80%, 85%, 90%, 95% or 99% identity with SEQ ID NO: 4 or SEQ ID NO: 8, and their reverse complements, which codifies the variable region of the light chain of the antibody. ### Claim 4 (depends on 1) An in vitro and/or ex vivo ADV infection diagnostic method of a biological sample, wherein the method comprises contacting the biological sample with the monoclonal antibody against ADV or a fragment thereof according to claim 1 and detecting the binding of the antibody to the antigen. ### Claim 5 (depends on 4) The in vitro and/or ex vivo diagnostic method according to claim 4, wherein the biological sample is selected from the group consisting of in vitro cells infected with ADV, nasal secretions, nasal washes, cerebrospinal fluid, pharyngeal secretions and/or bronchial washes or secretions. ### Claim 6 (depends on 4) The in vitro and/or ex vivo diagnostic method according to claim 4, wherein the technique used for the detection of the antibody with the antigen is selected from: ELISA, immunofluorescence, immunohistochemistry, immunochromatography, flow cytometry, cell sorter, immunoprecipitation and/or Western blot. ### Claim 7 (depends on 4) The in vitro and/or ex vivo diagnostic method according to claim 4, wherein the antibody or fragment thereof, is conjugated with a label which allows its detection. ### Claim 8 (depends on 7) The in vitro and/or ex vivo diagnostic method according to claim 7, wherein the antibody is bound to a label selected from the group consisting of biotin, metals, enzymes, proteins, fluorophores and radioactive isotopes. ### Claim 9 (depends on 7) The in vitro and/or ex vivo diagnostic method according to claim 7, wherein the antibody is attached to a solid support. ### Claim 10 (depends on 9) The in vitro and/or ex vivo diagnostic method according to claim 9, wherein the solid support is nitrocellulose, nylon membrane, magnetic spheres, or fluorescent spheres. ### Claim 11 (depends on 1) A diagnostic kit for detecting ADV comprising at least one monoclonal antibody against ADV, according to claim 1. ### Claim 12 (depends on 11) The diagnostic kit according to claim 11, wherein the antibody is attached to a solid support. ### Claim 13 (depends on 12) The diagnostic kit according to claim 12, wherein the solid support is nitrocellulose, nylon membrane, magnetic spheres, or fluorescent spheres. ### Claim 14 (depends on 11) The diagnostic kit according to claim 11, which corresponds to an immunochromatographic, multiplexed nucleic acid assay, flow cytometry, immunofluorescence, radioimmunoassay, Western blot, dot blot, ELISA, immunodiffusion or immunoprecipitation test for detecting ADV. ### Claim 15 (depends on 2) An in vitro and/or ex vivo ADV infection diagnostic method of a biological sample, wherein the method comprises contacting the biological sample with the monoclonal antibody against ADV or a fragment thereof according to claim 2 and detecting the binding of the antibody to the antigen. ### Claim 16 (depends on 2) A diagnostic kit for detecting ADV comprising at least one monoclonal antibody against ADV, according to claim 2. ### Claim 17 (depends on 12) The diagnostic kit according to claim 12, which corresponds to an immunochromatographic, multiplexed nucleic acid assay, flow cytometry, immunofluorescence, radioimmunoassay, Western blot, dot blot, ELISA, immunodiffusion or immunoprecipitation test for detecting ADV. ### Claim 18 (depends on 13) The diagnostic kit according to claim 13, which corresponds to an immunochromatographic, multiplexed nucleic acid assay, flow cytometry, immunofluorescence, radioimmunoassay, Western blot, dot blot, ELISA, immunodiffusion or immunoprecipitation test for detecting ADV.